The Pharmacopsychometric Triangle to Illustrate the Effectiveness of T-PEMF Concomitant with Antidepressants in Treatment Resistant Patients: A Double-Blind, Randomised, Sham-Controlled Trial Revisited with Focus on the Patient-Reported Outcomes

Table 3

Comparison of clinician-rated and patient-rated HAM-D₆. LOCF analysis.

HAM-D6	Clinician		Patient
	Active T-PEMF	Sham T-PEMF	Active T-PEMF	Sham T-PEMF
	(𝑁=21)	(𝑁=19)	(𝑁=21)	(𝑁=19)
Baseline	12.5 (2.1)	12.5 (2.0)	13.9 (2.2)	13.8 (2.5)
week 1	10.6 (2.9)*	11.7 (2.1)	10.9 (3.8)	11.2 (3.3)
week 2	9.7 (2.2)*	10.6 (2.8)	9.3 (3.0)*	11.5 (4.4)
week 3	8.8 (2.3)*	10.6 (3.1)	8.6 (3.4)**	11.9 (4.0)
week 4	7.9 (3.0)*	10.8 (2.8)	7.8 (3.3)**	12.0 (4.0)
week 5	6.9 (3.7)*	10.5 (3.2)	7.0 (4.5)**	10.8 (3.7)

* 𝑃≤.05.
** 𝑃≤.01.